The angiogenic peptide vascular endothelial growth factor (VEGF) is expressed in chronic sacral pressure ulcers

Chronic decubital lesions have a limited potential to heal. Evidence suggests that a lack of local revascularization is involved in this aetiology. The present study investigated the expression of one of the most important angiogenic factors, the vascular endothelial growth factor (VEGF), in different regions of sacral chronic decubital lesions and in normal skin by immunohistochemical, biochemical, molecular, and cell biology methods. To elucidate some of the factors responsible for the induction of VEGF in chronic skin ulcers, cultured fibroblasts were exposed to hypoxia and/or growth factors. In the central part (zone I) of chronic ulcers and in normal skin, immunostaining for VEGF remained largely negative. However, VEGF could be immunostained in cells in the granulation tissue adjacent to central necrosis (zone II). VEGF receptor 2 (VEGFR‐2; KDR) could also be identified in microvessels. High VEGF levels were present in homogenates from granulation tissue by enzyme‐linked immunosorbent assay (ELISA) and western blot experiments: low concentrations were found in areas of central necrosis and negligible amounts were present in normal skin. Reverse transcriptase‐polymerase chain reaction (RT‐PCR) showed that only the splice variants VEGF121 and VEGF165 were expressed. In cultured fibroblasts, hypoxia or platelet‐derived growth factor (PDGF) raised VEGF production. The angiogenic peptide VEGF is present in all zones of chronic decubital ulcers. Its strong expression within the adjacent granulation tissue supports the view that there is no deficiency of VEGF. VEGF may be involved in the healing process of chronic skin lesions, but it seems that loss of another factor may be responsible for the poor healing response. Copyright © 2003 John Wiley & Sons, Ltd.

[1]  W. Petersen,et al.  The angiogenic peptide vascular endothelial growth factor is expressed in foetal and ruptured tendons , 2001, Virchows Archiv.

[2]  T. Pufe,et al.  Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis. , 2001, The Journal of rheumatology.

[3]  T. Pufe,et al.  Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. , 2001, Brain research. Molecular brain research.

[4]  G. Sibbald,et al.  Recombinant human platelet‐derived growth factor‐BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open‐label clinical evaluation of efficacy , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[5]  S. Carta,et al.  Pressure ulcer research issues in surgical patients. , 2000, Advances in skin & wound care.

[6]  Jerry S. Vandeberg,et al.  Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. , 2000, Annals of surgery.

[7]  K. Püschel,et al.  Häufigkeit und Ausmaß einer Osteomyelitis bei höhergradigen Dekubitalulzera – Eine histomorphologische Analyse nach unentkalkter Präparation des Os sacrum , 2000, Rechtsmedizin.

[8]  G. Onder,et al.  Effect of topical application of nerve-growth factor on pressure ulcers , 1999, The Lancet.

[9]  N. Ferrara Molecular and biological properties of vascular endothelial growth factor , 1999, Journal of Molecular Medicine.

[10]  Napoleone Ferrara,et al.  VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation , 1999, Nature Medicine.

[11]  L. Eckhart,et al.  Reverse Transcription-Polymerase Chain Reaction Products of Alternatively Spliced mRNAs Form DNA Heteroduplexes and Heteroduplex Complexes* , 1999, The Journal of Biological Chemistry.

[12]  J. Held-Feindt,et al.  Molecular analysis of the somatostatin receptor subtype 2 in human glioma cells. , 1999, Brain research. Molecular brain research.

[13]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  T. K. Hunt,et al.  The future of recombinant growth factors in wound healing. , 1998, American journal of surgery.

[15]  G. Siemeister,et al.  Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression , 1997, Oncogene.

[16]  Mayumi Ono,et al.  Induction of Vascular Endothelial Growth Factor by Tumor Necrosis Factor α in Human Glioma Cells , 1996, The Journal of Biological Chemistry.

[17]  M. Klagsbrun,et al.  Vascular endothelial growth factor and its receptors. , 1996, Cytokine & growth factor reviews.

[18]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[19]  W. Kenney,et al.  Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. , 1995, The Journal of clinical investigation.

[20]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[21]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[22]  J. Erusalimsky,et al.  Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. , 1995, Circulation.

[23]  N. Olsen,et al.  Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue , 1994, The Journal of experimental medicine.

[24]  D Norton,et al.  Calculating the risk: reflections on the Norton Scale. , 1989, Decubitus.

[25]  D. E. Sharland,et al.  The Management and Prevention of Pressure Sores , 1982 .

[26]  J. D. Shea Pressure sores: classification and management. , 1975, Clinical orthopaedics and related research.

[27]  M. Tsokos,et al.  Pressure sores: epidemiology, medico-legal implications and forensic argumentation concerning causality , 2000, International Journal of Legal Medicine.

[28]  J. Haalboom,et al.  Pressure-induced skin lesions in pigs: reperfusion injury and the effects of vitamin E. , 2000, Journal of wound care.

[29]  P. Vogt,et al.  [Clinical application of growth factors and cytokines in wound healing]. , 2000, Zentralblatt fur Chirurgie.

[30]  G. Bennett,et al.  Pressure ulcers: prevalence, etiology, and treatment modalities. A review. , 1994, American journal of surgery.